STOCK TITAN

Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Dyne Therapeutics Inc ownership update: The Vanguard Group filed an amended Schedule 13G/A stating it reports no beneficial ownership of Dyne Therapeutics common stock following an internal realignment. The filing lists Amount beneficially owned: 0 and Percent of class: 0%.

The filing cites an internal realignment effective January 12, 2026 and is signed on 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings and reports zero beneficial ownership of Dyne.

The disclosure states The Vanguard Group completed an internal realignment on January 12, 2026 and, in reliance on SEC Release No. 34-39538, now reports holdings of certain subsidiaries separately. The form records 0 shares and 0% ownership.

Cash‑flow treatment and specific subsidiary holdings are not listed in this excerpt; subsequent filings by Vanguard subsidiaries may show where prior holdings are reported.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What did The Vanguard Group report for DYN in this amendment?

The Vanguard Group reported 0 shares beneficially owned and 0% of the outstanding class. The amendment attributes the change to an internal realignment and separate reporting of subsidiaries effective January 12, 2026.

Why does Vanguard now report zero ownership of Dyne (DYN)?

Vanguard cites an internal realignment on January 12, 2026 and reliance on SEC Release No. 34-39538, after which certain subsidiaries report holdings separately and Vanguard no longer reports beneficial ownership for those subsidiary-held securities.

Does this filing disclose which Vanguard subsidiary holds Dyne shares?

No; the amendment explains subsidiaries will report disaggregated ownership but does not list specific subsidiary names or share counts for Dyne. Look for additional 13G/A filings by Vanguard affiliates for subsidiary-level disclosures.

What date is the signature and who signed the amendment?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026, certifying the amended Schedule 13G/A for The Vanguard Group.

Does this filing change Dyne's outstanding share count or affect shareholder control?

This filing only reports The Vanguard Group's beneficial ownership as 0 shares (0%) and does not state any change to Dyne's outstanding share count or indicate any change in shareholder control in the provided excerpt.
Dyne Therapeutics, Inc.

NASDAQ:DYN

View DYN Stock Overview

DYN Rankings

DYN Latest News

DYN Latest SEC Filings

DYN Stock Data

3.06B
154.96M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM